Investors

Press Releases

Date Title View
Toggle Summary Momenta Pharmaceuticals Announces Goals for Glycoprotein Program
Momenta Pharmaceuticals Announces Goals for Glycoprotein Program CAMBRIDGE, Mass., Jan 13, 2005 /PRNewswire-FirstCall via COMTEX/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, today announced its goals relating to the
View HTML
Toggle Summary Momenta Pharmaceuticals to Present at JP Morgan's 23rd Annual Healthcare Conference
Momenta Pharmaceuticals to Present at JP Morgan's 23rd Annual Healthcare Conference CAMBRIDGE, Mass., Jan. 6 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, announced today that its Chairman and
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Appointments in Manufacturing Management and Investor Relations
Momenta Pharmaceuticals Announces Appointments in Manufacturing Management and Investor Relations CAMBRIDGE, Mass., Nov. 16 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, today announced the
View HTML
Toggle Summary Momenta Pharmaceuticals to Present at SG Cowen 5th Annual Global Health Care Conference
Momenta Pharmaceuticals to Present at SG Cowen 5th Annual Global Health Care Conference CAMBRIDGE, Mass., Nov. 12 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, announced today that its Chairman
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Financial Results for Third Quarter 2004
Momenta Pharmaceuticals Reports Financial Results for Third Quarter 2004 CAMBRIDGE, Mass., Nov. 5 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, today announced its financial results for the
View HTML
Toggle Summary Momenta Pharmaceuticals to Present at CIBC World Markets Fifteenth Annual Healthcare Conference
Momenta Pharmaceuticals to Present at CIBC World Markets Fifteenth Annual Healthcare Conference CAMBRIDGE, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, announced today that its
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Conference Call Discussing Third Quarter 2004 Financial Results
Momenta Pharmaceuticals to Webcast Conference Call Discussing Third Quarter 2004 Financial Results CAMBRIDGE, Mass., Oct. 28 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, will report financial
View HTML
Toggle Summary Momenta Pharmaceuticals' Technology Featured in Nature Reviews
Momenta Pharmaceuticals' Technology Featured in Nature Reviews Article Highlights the Potential of Sugars for Therapeutic Drug Development CAMBRIDGE, Mass., Oct. 12 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar
View HTML
Toggle Summary Momenta Pharmaceuticals To Be Included in Russell 3000(R) Index
Momenta Pharmaceuticals To Be Included in Russell 3000(R) Index CAMBRIDGE, Mass., Sept. 16 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) announced today that it will be included in the Russell 3000 Index when the Index is reconstituted effective October 1, 2004 to reflect
View HTML
Toggle Summary Momenta Pharmaceuticals to Present at ThinkEquity Partners Growth Conference
Momenta Pharmaceuticals to Present at ThinkEquity Partners Growth Conference CAMBRIDGE, Mass., Sept. 14 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, announced today that its Chairman and Chief
View HTML